Identification of Potential Serum Protein Biomarkers in Thymoma with Myasthenia Gravis After Docetaxel Treatment
Abstract Introduction Myasthenia gravis (MG) is a devastating acquired autoimmune disease that can seriously affect the patient’s quality of life. It is also a common complication of thymoma. Previous studies have shown that docetaxel alleviates myasthenic symptoms in thymoma with MG (TMG). However,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-02-01
|
| Series: | Neurology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40120-023-00442-3 |
| _version_ | 1797853499144273920 |
|---|---|
| author | Hongxia Yang Guoyan Qi Huimin Dong Ze Liu Mei Ma Peng Liu |
| author_facet | Hongxia Yang Guoyan Qi Huimin Dong Ze Liu Mei Ma Peng Liu |
| author_sort | Hongxia Yang |
| collection | DOAJ |
| description | Abstract Introduction Myasthenia gravis (MG) is a devastating acquired autoimmune disease that can seriously affect the patient’s quality of life. It is also a common complication of thymoma. Previous studies have shown that docetaxel alleviates myasthenic symptoms in thymoma with MG (TMG). However, little is known about the protein expression profiles and biomarkers for efficacy after docetaxel treatment. Methods We recruited 9 healthy controls and 30 patients with TMG for the serum proteomics study with data-independent acquisition (DIA) technology. We further recruited additional 30 patients for the key protein validation by enzyme-linked immunosorbent assay (ELISA). Results We identified 43 proteins by trend analysis and analyzed the interaction between these proteins and MG pathogenic proteins from the DisGNET database and the correlation analysis with clinical data of patients with TMG. Among these, KRAS and SELP were screened out and validated. KRAS and SELP increased in patients with TMG and decreased significantly after docetaxel treatment. Conclusions Our study revealed that the serum proteins were differentially expressed after docetaxel treatment, suggesting their important role in patients with TMG, as well as the critical role of KRAS and SELP as biomarkers in evaluating the efficacy of docetaxel treatment. |
| first_indexed | 2024-04-09T19:50:34Z |
| format | Article |
| id | doaj.art-1c81590394a740c786dbb7a43e6d059c |
| institution | Directory Open Access Journal |
| issn | 2193-8253 2193-6536 |
| language | English |
| last_indexed | 2024-04-09T19:50:34Z |
| publishDate | 2023-02-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Neurology and Therapy |
| spelling | doaj.art-1c81590394a740c786dbb7a43e6d059c2023-04-03T05:45:17ZengAdis, Springer HealthcareNeurology and Therapy2193-82532193-65362023-02-0112255957010.1007/s40120-023-00442-3Identification of Potential Serum Protein Biomarkers in Thymoma with Myasthenia Gravis After Docetaxel TreatmentHongxia Yang0Guoyan Qi1Huimin Dong2Ze Liu3Mei Ma4Peng Liu5Center of Treatment of Myasthenia Gravis, People’s Hospital of Shijiazhuang Affiliated to Hebei Medical UniversityCenter of Treatment of Myasthenia Gravis, People’s Hospital of Shijiazhuang Affiliated to Hebei Medical UniversityCenter of Treatment of Myasthenia Gravis, People’s Hospital of Shijiazhuang Affiliated to Hebei Medical UniversityCenter of Treatment of Myasthenia Gravis, People’s Hospital of Shijiazhuang Affiliated to Hebei Medical UniversityCenter of Treatment of Myasthenia Gravis, People’s Hospital of Shijiazhuang Affiliated to Hebei Medical UniversityCenter of Treatment of Myasthenia Gravis, People’s Hospital of Shijiazhuang Affiliated to Hebei Medical UniversityAbstract Introduction Myasthenia gravis (MG) is a devastating acquired autoimmune disease that can seriously affect the patient’s quality of life. It is also a common complication of thymoma. Previous studies have shown that docetaxel alleviates myasthenic symptoms in thymoma with MG (TMG). However, little is known about the protein expression profiles and biomarkers for efficacy after docetaxel treatment. Methods We recruited 9 healthy controls and 30 patients with TMG for the serum proteomics study with data-independent acquisition (DIA) technology. We further recruited additional 30 patients for the key protein validation by enzyme-linked immunosorbent assay (ELISA). Results We identified 43 proteins by trend analysis and analyzed the interaction between these proteins and MG pathogenic proteins from the DisGNET database and the correlation analysis with clinical data of patients with TMG. Among these, KRAS and SELP were screened out and validated. KRAS and SELP increased in patients with TMG and decreased significantly after docetaxel treatment. Conclusions Our study revealed that the serum proteins were differentially expressed after docetaxel treatment, suggesting their important role in patients with TMG, as well as the critical role of KRAS and SELP as biomarkers in evaluating the efficacy of docetaxel treatment.https://doi.org/10.1007/s40120-023-00442-3Myasthenia gravisThymomaDocetaxel |
| spellingShingle | Hongxia Yang Guoyan Qi Huimin Dong Ze Liu Mei Ma Peng Liu Identification of Potential Serum Protein Biomarkers in Thymoma with Myasthenia Gravis After Docetaxel Treatment Neurology and Therapy Myasthenia gravis Thymoma Docetaxel |
| title | Identification of Potential Serum Protein Biomarkers in Thymoma with Myasthenia Gravis After Docetaxel Treatment |
| title_full | Identification of Potential Serum Protein Biomarkers in Thymoma with Myasthenia Gravis After Docetaxel Treatment |
| title_fullStr | Identification of Potential Serum Protein Biomarkers in Thymoma with Myasthenia Gravis After Docetaxel Treatment |
| title_full_unstemmed | Identification of Potential Serum Protein Biomarkers in Thymoma with Myasthenia Gravis After Docetaxel Treatment |
| title_short | Identification of Potential Serum Protein Biomarkers in Thymoma with Myasthenia Gravis After Docetaxel Treatment |
| title_sort | identification of potential serum protein biomarkers in thymoma with myasthenia gravis after docetaxel treatment |
| topic | Myasthenia gravis Thymoma Docetaxel |
| url | https://doi.org/10.1007/s40120-023-00442-3 |
| work_keys_str_mv | AT hongxiayang identificationofpotentialserumproteinbiomarkersinthymomawithmyastheniagravisafterdocetaxeltreatment AT guoyanqi identificationofpotentialserumproteinbiomarkersinthymomawithmyastheniagravisafterdocetaxeltreatment AT huimindong identificationofpotentialserumproteinbiomarkersinthymomawithmyastheniagravisafterdocetaxeltreatment AT zeliu identificationofpotentialserumproteinbiomarkersinthymomawithmyastheniagravisafterdocetaxeltreatment AT meima identificationofpotentialserumproteinbiomarkersinthymomawithmyastheniagravisafterdocetaxeltreatment AT pengliu identificationofpotentialserumproteinbiomarkersinthymomawithmyastheniagravisafterdocetaxeltreatment |